FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
Obesity is now linked to at least 13 types of cancer, making it one of the most preventable cancer risk factors in the United ...
In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...
As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...
This article was reviewed by Knox Beasley. Key Takeaways: 1mg oral finasteride effectively treats hair loss and is the ...
Are time commitments related to cancer care toxic? Depends on who you ask.The term “time toxicity” has become cancer jargon over the past few years, sparking research into how much time patients spend ...
LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...
Everyday Health on MSN
How to manage LEMS weakness while treating lung cancer
Learn how to tell the difference between these two common symptoms.
Roche shares have dropped after its oral breast cancer drug giredestrant failed to show benefits in a key phase III clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results